NCT02254005View on ClinicalTrials.gov

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2002

Primary Completion Date

December 1, 2004

Conditions
Breast Neoplasms
Interventions
DRUG

bivatuzumab mertansine

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY